Articles tagged with Statins
A study found that older patients with stable cardiovascular disease can benefit from high-dose statins, which lowered LDL cholesterol levels and reduced the risk of major cardiovascular events. The study suggests that aggressive use of high-dose statin therapy can be beneficial for these patients.
Recent research confirms statins are well-tolerated and effective in reducing cardiovascular disease risk. The review highlights their impact on LDL cholesterol levels and safety profile, including rare but potential muscle-related side effects.
Research on statin effectiveness found to be influenced by funding source, with results favoring sponsored products. Additionally, a study on breast cancer cell survival discovered that vascular endothelial growth factor (VEGF) acts as an internal autocrine survival factor through its receptor VEGFR1.
A study of nearly 200 statin-drug comparisons found that funding source greatly impacts results, with industry-funded trials more likely to favor the test drug. The analysis also revealed a lack of clinical measures of outcome, such as heart attacks or mortality, in many trials.
A Mayo Clinic research team has developed a simple tool to enhance medication adherence in diabetes patients, with 84% of users showing improved compliance. The decision aid sparks conversation between doctors and patients about medication risks and benefits, leading to better-informed decisions.
Researchers found that statin therapy improved ALT values in chronic hepatitis C patients with abnormal liver enzymes. The study also showed a higher sustained viral response rate when adding statins to standard peginterferon and ribavirin treatment, suggesting a possible new treatment option.
Researchers found a direct correlation between statin use and decreased prostate-specific antigen levels, as well as lower mortality rates from prostate cancer. The study suggests that increased statin use may be contributing to declining prostate cancer mortality rates in the US between 1993 and 2003.
Researchers found that statin drugs can lower resting sympathetic nervous system activity, a factor associated with increased mortality in heart failure patients. This decrease in activity is linked to improved health outcomes and reduced risk of heart failure and sudden cardiac death.
Treatment with Simvastatin significantly improved spatial memory in mice genetically bred to have an Alzheimer's-like disease, with more pronounced effects in males. The study found that statin increased levels of nNOS, a substance that causes dilation of blood vessels and improves circulation to the brain.
A new study finds that higher doses of statins are cost-effective for patients with recent heart attacks, but may not provide significant benefits for those with stable coronary artery disease. The analysis could help evaluate the cost-effectiveness of other medications and treatments.
Researchers at Johns Hopkins found that statins significantly reduce the risk of sepsis in patients undergoing kidney dialysis. The study, published in JAMA, followed 1041 patients for 10 years and found a 41-case risk in the statin group compared to 110 cases in the non-statin group.
A recent study published in The Lancet found that eicosapentaenoic acid (EPA) supplementation reduced major coronary events by 19% in Japanese hypercholesterolaemic patients taking statins. This significant reduction also translated to a lower incidence of non-fatal myocardial infarction, unstable angina, and coronary revascularisation.
Clinical trials show statin therapy promotes regression of coronary atherosclerosis through significant reductions in LDL-C and increases in HDL-C. Patients experiencing substantial decreases in LDL-C (<87.5 mg/dL) and percentage increases in HDL-C (>7.5%) exhibit notable atheroma regression.
A study found that middle-aged men with shorter telomeres were more likely to develop coronary heart disease. Statin treatment reduced the risk of heart disease in these individuals, suggesting a potential biomarker for personalized medicine.
New research suggests that taking prescribed medications like statins and beta-blockers following a heart attack is associated with longer survival. Adherence to these medications was found to be linked to improved mortality outcomes, with the strongest association observed for patients who took their medication as prescribed.
Recent research suggests that regular statin use is not linked to lower colorectal cancer risk, while folate intake does not appear to impact breast cancer risk. However, monitoring of thyroid function may be necessary for patients taking the medication sunitinib, which can cause fatigue and hypothyroidism.
Research reveals that statins increase the risk of acute pancreatitis by 40%, but the occurrence is still relatively rare. The study found that patients on low and high doses developed pancreatitis, suggesting that starting at a low dose may not prevent the side effect.
Thousands of statin users worldwide are suffering preventable heart attacks due to sub-optimal use or low doses. Researchers found that only 20% of low-dose users experienced significant risk reduction compared to high-dose users.
A meta-analysis of seven clinical trials found that statins can reduce the risk of major heart and cerebrovascular events in healthy individuals. However, these medications do not appear to provide significant benefits for those without cardiovascular disease or abnormal cholesterol levels.
Patients with heart failure who started statin therapy had a 24% lower risk of death and a 21% lower risk of hospitalization compared to non-users. The study, published in JAMA, found that statins effectively lowered LDL cholesterol levels and improved clinical outcomes.
New research reveals statins can significantly reduce stroke incidence, myocardial infarction, and all-cause death in non-revascularized patients with severe carotid arterial disease. Statin treatment also showed no significant differences in age, gender, or other factors.
Current and former smokers who used statins had lower lung function decline than those not using statins, regardless of smoking status. Statin use was found to decrease the decline in lung function by 10.3% in controls versus 1.3% in statin users.
A team of researchers reviews existing research on LDL cholesterol and heart health, concluding that there is no valid evidence to support ultra-low LDL targets. They suggest focusing on statin therapy for high-risk patients regardless of their cholesterol levels.
A systematic review of 13 clinical trials found that early, intensive statin therapy reduced cardiovascular death, unstable angina, and revascularization. The benefits were sustained for two years, with slightly less than a 20% reduction in adverse coronary events.
Patients can self-report muscle weakness, fatigue, cognitive problems, and mood changes associated with statin use on a new web site. The site aims to gather information on side effects and provide education on minimizing health risks.
Study suggests that statins may be beneficial for preventing complications of metabolic syndrome, a condition characterized by low-grade inflammation and insulin resistance. The researchers found marked reductions in inflammatory biomarkers and improvements in vascular health in patients treated with statins.
Researchers discovered statins inhibit HCV replication without killing host cells. Fluvastatin showed strongest effect in combination with interferon, leading to effective HCV RNA replication inhibition.
A large cohort study found that statin users had a significantly lower risk of developing age-related nuclear cataract compared to non-users. The odds of developing nuclear cataract were 40% lower in statin users after adjusting for other factors, such as smoking and diabetes.
Researchers suggest that cholesterol-lowering drugs like statins could be useful in treating and preventing severe complications of the flu during a pandemic. Statins have anti-inflammatory and immunomodulatory effects that may also benefit people with influenza, making them a potential alternative to vaccines.
A new study has compared national, European, and US recommendations for statin treatment in British men to prevent cardiovascular disease. The research found that the UK's National Health Service Framework makes the least effective use of available evidence on prevention.
A study of over 156,000 post-menopausal women found that taking hydrophobic statins was associated with a 18% decreased incidence of breast cancer. However, no association was found between statin use and breast cancer risk in general. Further research is needed to confirm this finding.
A new study found that postmenopausal women who use statins have the same risk of invasive breast cancer as those who do not. Hydrophobic statins were associated with an 18% decreased risk of breast cancer, but individual statin associations warrant further research.
A study of over 16,000 patients found that early statin therapy reduces the risk of death by 22% and cardiovascular death by 25%. The treatment also shows promise in preventing another episode of unstable angina and reducing the need for coronary bypass surgery.
Researchers found that long-term use of statins increased retinal blood flow and reduced intraocular pressure in healthy men. The findings suggest a potential therapy for diabetic retinopathy, a condition linked to reduced blood flow in the eye.
A meta-analysis of randomized controlled trials found no statistically significant risk reductions from early statin therapy for total death, MI, stroke, cardiovascular death, fatal or nonfatal MI, or revascularization procedures. Serious adverse events associated with early initiation of statins are rare.
A new study found that patients who saw visual proof of plaque buildup after an EBT scan were more likely to comply with prescribed statin therapy, exceeding 90% compliance. The study also suggests that this method can improve overall health behaviors beyond just medication adherence.
A study found that regular religious attendance is linked to a lifespan extension of 1.8-3.1 years, comparable to statin therapy (2.1-3.7 years) and physical exercise (3.0-5.1 years). Religious attendance may also be more cost-effective than statins.
A team from Harvard Medical School found that matrix metalloproteinase-9 (MMP-9) helps remodel brain tissue seven to 14 days after a stroke, potentially aiding recovery. High levels of MMPs were detected in the peri-infarct cortex, an area involved in stroke recovery.
A recent study found that low levels of LDL cholesterol, even in individuals with high-risk factors, can dramatically reduce the incidence of coronary events. The analysis identified three forms of a gene known as PCSK9 associated with significant reductions in plasma levels of LDL cholesterol.
Researchers have found that combining Lipitor with Glatiramer acetate can prevent or diminish paralysis in mice with experimental autoimmune encephalomyelitis, a model disease closely resembling MS. The study demonstrates the potential of this combination therapy for treating central nervous system autoimmunity.
Statins have been shown to significantly reduce all-cause mortality in patients treated early for acute coronary syndromes, with a moderate reduction in stroke risk. Beta-blockers also demonstrate improved survival benefits when prescribed at discharge for heart failure patients, reducing the risk of death by half.
Research shows that high-risk hypertensive patients are frequently prescribed antihypertensive therapy but rarely receive concomitant statin therapy. Despite the potential to significantly reduce cardiovascular risk, over half of these patients do not receive cholesterol-lowering statins during their first year of treatment.
A study showed that very high-intensity statin therapy can induce regression of coronary atherosclerosis, measured by percent atheroma volume. Rosuvastatin treatment led to significant decreases in low-density lipoprotein cholesterol and increases in high-density lipoprotein cholesterol.
The ASTEROID trial found that intensive statin therapy resulted in significant regression of atherosclerosis, with mean LDL cholesterol dropping by 53.2% and HDL increasing by 14.7%. The study suggests that very low LDL levels accompanied by raised HDL can partially reverse plaque buildup in coronary arteries.
A U of T study found that a combination of viscous fibres, soy protein, almonds, and plant sterol margarine can significantly lower cholesterol levels. After 12 months, over 30% of participants successfully adhered to the diet and lowered their cholesterol by more than 20%.
The article discusses scientific fraud prevention and the growing concern of community-acquired MRSA infections. The key responsibilities for addressing misconduct can be shared among institutions, co-authors, and journal editors.
A Stanford-Kaiser study suggests that statins and beta-blockers can significantly reduce the risk of heart attack in patients with high blood pressure or high cholesterol. The study found that these medications were effective in reducing the risk of heart attack by more than half, even when other treatments for high cholesterol failed.
A recent study published in the Journal of General Internal Medicine found that nearly 10 million more adults have high LDL-C (
Researchers found that statins, such as fluvastatin, can induce apoptosis in RA synovial cells through the inhibition of protein geranygeranylation. This suggests that statins may be ideal therapeutic agents for treating rheumatoid arthritis. Further clinical trials are proposed to confirm these findings.
A large study found that statin use was associated with a 19% reduced risk of sepsis in patients with cardiovascular disease. The study analyzed data from over 69,000 people and suggested that statins may be used to prevent sepsis in this population.
A meta-analysis of randomized controlled trials found that statins did not reduce the incidence of cancer or cancer death. The study evaluated 86,936 participants and 26 trials, with no reductions noted for specific types of cancer.
A new study suggests that investing in existing medical treatments could be more effective in saving lives than developing new ones. The research highlights the importance of addressing system barriers and improving access to care for underprivileged patients.
Researchers found that pravastatin increased endogenous stem cells for cardiac repair, independent of cholesterol-lowering action. High doses improved cardiac function and coronary blood flow in hibernating myocardium, a condition where heart cells reduce their function due to insufficient blood flow.
The IDEAL study found that intensive LDL-C lowering therapy in patients with previous myocardial infarction did not significantly reduce primary end points but showed reduced risk of secondary composite endpoints and nonfatal acute MI. No differences were observed in cardiovascular or all-cause mortality.
Researchers identified a new genetic variation associated with statin response, finding that 9% of African Americans and 0.2% of Caucasians carry the variation. The study suggests that genetic differences may affect cholesterol lowering and cardiovascular outcomes.
Patients who received statin medication before carotid artery surgery experienced a three-fold lower stroke rate and five-fold lower mortality rate compared to those who did not. Statins may reduce the risk of stroke by reducing plaque fragmentation or clot formation, although the exact mechanism is unclear.
Researchers discovered that Lovastatin can reverse learning and attention deficits in adult Nf1 mutant mice, suggesting a potential treatment for the disorder. The findings also show that cognitive deficits associated with NF1 are not irreversible developmental deficits.
Researchers found that statin drugs can reverse learning deficits in mice with Neurofibromatosis type 1 (NF1), a condition affecting five percent of the world population. The treatment enables normal brain cell communication, creating physical changes in the brain and improving memory.
Researchers analyzed data from 79,994 women to evaluate associations of statins, lipid-lowering drugs, and serum cholesterol levels with breast cancer. No link was found between these factors and breast cancer risk.
Researchers analyzed data from a large trial and found no safety concerns for patients with very low LDL levels. The study suggests that intensive statin therapy may be beneficial even when LDL levels drop below targeted levels.